Bioengineering 2018, 5(4), 83; https://doi.org/10.3390/bioengineering5040083
GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
1
Department of Biomedical Engineering and Biotechnology, University of Massachusetts, Lowell, MA 01854, USA
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3
Biomolecular Characterization Lab, Core Research Facility, University of Massachusetts Lowell, Lowell, MA 01854, USA
4
Department of Chemical Engineering, University of Massachusetts, Lowell, MA 01854, USA
*
Author to whom correspondence should be addressed.
Received: 17 August 2018 / Revised: 4 October 2018 / Accepted: 6 October 2018 / Published: 9 October 2018
(This article belongs to the Special Issue Nanoparticles in Therapeutic Applications)
Abstract
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications. View Full-TextKeywords:
GSK461364A; Glioblastoma Multiforme; polymeric nanoparticles; cytotoxicity; enhanced permeability and retention; polo-like kinase inhibitor; oncology; oncomedicine; U-87 MG
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Velpurisiva, P.; Piel, B.P.; Lepine, J.; Rai, P. GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM). Bioengineering 2018, 5, 83.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Bioengineering
EISSN 2306-5354
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert